Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Serono Launches Cyanokit In Japan

This article was originally published in PharmAsia News

Executive Summary

On March 19, Tokyo-based Merck Serono Co. launched Cyanokit (hydroxocobalamin) in Japan. Approved by Japan's Ministry of Health in September 2007, Cyanokit treats cyanide poisoning caused by hydrocyanic acid and its derivatives in both adults and children, and it will primarily be distributed to hospitals and emergency care centers. Administrated by intravenous infusion, Cyanokit is commercially available in the U.S. and recently approved in the European Union. Merck Serono applauded the launch of Cyanokit as a key milestone for emergency health professionals in Japan. Cyanide poisoning is primarily caused by smoke inhalation during closed-space structural fires. (Click here for more-Japanese language

You may also be interested in...



Deals Shaping The Medical Industry, April 2020

This month’s column covers deals announced between 1-23 April 2020. 

WHO Prequalifies Celltrion’s Rituximab

Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.

EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times

26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel